Dossier assessment

Delgocitinib (moderate to severe chronic hand eczema) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A24-107
Last updated

Report documents

  1. Extract of dossier assessment

    Delgocitinib (moderate to severe chronic hand eczema) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 362 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A24-107_en
  2. Dossier assessment

    Delgocitinib (moderate to severe chronic hand eczema) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 533 kB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A24-107

Dossier assessment

Indication:

Adult patients with moderate to severe chronic hand eczema for whom topical corticosteroids are inadequate or inappropriate

Result of dossier assessment:

Added benefit not proven

Additional information

Federal Joint Committee (G-BA)

03-04-2025 A G-BA decision was published.
G-BA documents on this decision

Project details

Project no.
A24-107
Commission
Commission awarded on 15.10.2024 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Skin and hair
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A24-107_en

Connected Projects

  1. Addendum

    Delgocitinib (moderate to severe chronic hand eczema) – Addendum to Project A24-107

    Project no.
    A25-37
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form